Metabolomic high-content nuclear magnetic resonance-based drug screening of a kinase inhibitor library.

Metabolism is altered in many highly prevalent diseases and is controlled by a complex network of intracellular regulators. Monitoring cell metabolism during treatment is extremely valuable to investigate cellular response and treatment efficacy. Here we describe a nuclear magnetic resonance-based method for screening of the metabolomic response of drug-treated mammalian cells in a 96-well format. We validate the method using drugs having well-characterized targets and report the results of a screen of a kinase inhibitor library. Four hits are validated from their action on an important clinical parameter, the lactate to pyruvate ratio. An eEF-2 kinase inhibitor and an NF-kB activation inhibitor increased lactate/pyruvate ratio, whereas an MK2 inhibitor and an inhibitor of PKA, PKC and PKG induced a decrease. The method is validated in cell lines and in primary cancer cells, and may have potential applications in both drug development and personalized therapy.

[1]  Frank H. P. Fitzek,et al.  The Medium is the Message , 2006, 2006 IEEE International Conference on Communications.

[2]  Richard R. Ernst,et al.  Homonuclear broad band decoupling and two-dimensional J-resolved NMR spectroscopy , 1976 .

[3]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[4]  S Gail Eckhardt,et al.  NMR-based metabolomics: translational application and treatment of cancer. , 2007, Current opinion in molecular therapeutics.

[5]  Mark R. Viant,et al.  Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation , 2007, BMC Bioinformatics.

[6]  Jorge Cortes,et al.  Systems approaches and algorithms for discovery of combinatorial therapies. , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.

[7]  R. Kishony,et al.  Resolution of gene regulatory conflicts caused by combinations of antibiotics. , 2011, Molecular cell.

[8]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[9]  Jens O Krömer,et al.  Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. , 2010, Analytical biochemistry.

[10]  Helen M. Parsons,et al.  Effects of the application of different window functions and projection methods on processing of 1H J-resolved nuclear magnetic resonance spectra for metabolomics. , 2008, Analytica chimica acta.

[11]  S. Opella,et al.  NMR structure determination of a membrane protein with two transmembrane helices in micelles: MerF of the bacterial mercury detoxification system. , 2005, Biochemistry.

[12]  A. Weiss,et al.  Induction of NF-kappaB by the Akt/PKB kinase. , 1999, Current biology : CB.

[13]  J. Lindon,et al.  Pharmaco-metabonomic phenotyping and personalized drug treatment , 2006, Nature.

[14]  High-throughput NMR spectroscopy , 2004, Analytical and bioanalytical chemistry.

[15]  H. Senn,et al.  Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. , 2006, Analytical chemistry.

[16]  N. York,et al.  A review of available literature , 2012 .

[17]  Robert Nadon,et al.  Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.

[18]  U. Günther,et al.  Hypoxia Triggers Major Metabolic Changes in AML Cells without Altering Indomethacin-Induced TCA Cycle Deregulation , 2010, ACS chemical biology.

[19]  Z. Hall.  Cancer , 1906, The Hospital.

[20]  D. Kell,et al.  Metabolic footprinting and systems biology: the medium is the message , 2005, Nature Reviews Microbiology.

[21]  A. Weiss,et al.  Induction of NF-κB by the Akt/PKB kinase , 1999, Current Biology.

[22]  John N Weinstein,et al.  MicroRNA expression profiles for the NCI-60 cancer cell panel , 2007, Molecular Cancer Therapeutics.

[23]  U. Alon,et al.  Protein Dynamics in Drug Combinations: a Linear Superposition of Individual-Drug Responses , 2010, Cell.

[24]  A. M. Gil,et al.  Analytical approaches toward successful human cell metabolome studies by NMR spectroscopy. , 2009, Analytical chemistry.

[25]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[26]  Yan Cheng,et al.  Cytoprotective Effect of the Elongation Factor-2 Kinase-Mediated Autophagy in Breast Cancer Cells Subjected to Growth Factor Inhibition , 2010, PloS one.

[27]  M. Viant,et al.  High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. , 2008, Analytical biochemistry.

[28]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[29]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[30]  Anne Kümmel,et al.  Integration of Multiple Readouts into the Z' Factor for Assay Quality Assessment , 2010, Journal of biomolecular screening.

[31]  D. L. Taylor,et al.  High content screening applied to large-scale cell biology. , 2004, Trends in biotechnology.

[32]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[33]  R. Edden,et al.  Suppression of strong coupling artefacts in J-spectra. , 2005, Journal of magnetic resonance.

[34]  J. Kelleher,et al.  Metabolomic and Mass Isotopomer Analysis of Liver Gluconeogenesis and Citric Acid Cycle , 2008, Journal of Biological Chemistry.

[35]  A. J. Shaka,et al.  Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients , 1995 .

[36]  Scott A. Bradley,et al.  Fermentanomics: monitoring mammalian cell cultures with NMR spectroscopy. , 2010, Journal of the American Chemical Society.

[37]  Ludwig,et al.  NMRLAB-Advanced NMR data processing in matlab , 2000, Journal of magnetic resonance.

[38]  Tadashi Okamoto,et al.  Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. , 2003, Cancer research.

[39]  Royston Goodacre,et al.  Effective quenching processes for physiologically valid metabolite profiling of suspension cultured Mammalian cells. , 2009, Analytical chemistry.

[40]  Jason W. Locasale,et al.  Evidence for an Alternative Glycolytic Pathway in Rapidly Proliferating Cells , 2010, Science.

[41]  Monya Baker,et al.  Academic screening goes high-throughput , 2010, Nature Methods.

[42]  V. Avramis,et al.  Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia , 2006, International journal of nanomedicine.

[43]  David S Wishart,et al.  Towards automatic metabolomic profiling of high-resolution one-dimensional proton NMR spectra , 2011, Journal of biomolecular NMR.

[44]  John L Markley,et al.  Metabolite identification via the Madison Metabolomics Consortium Database , 2008, Nature Biotechnology.

[45]  M. Nilsson,et al.  Isomer resolution by micelle-assisted diffusion-ordered spectroscopy. , 2009, Analytical chemistry.

[46]  L B Nash,et al.  Seeing is believing , 2013, BDJ.

[47]  S. Gottschalk,et al.  Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells , 2004, Clinical Cancer Research.

[48]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[49]  M. Leach,et al.  Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. , 2005, Cancer research.

[50]  Wolfgang Link,et al.  High content screening: seeing is believing. , 2010, Trends in biotechnology.

[51]  H. Erfle,et al.  High-throughput RNAi screening by time-lapse imaging of live human cells , 2006, Nature Methods.

[52]  B. Shushan.  A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. , 2010, Mass spectrometry reviews.

[53]  Mark R. Viant,et al.  Metabolomic Profiling of Drug Responses in Acute Myeloid Leukaemia Cell Lines , 2009, PloS one.

[54]  Julian L. Griffin,et al.  Metabolic profiles of cancer cells , 2004, Nature Reviews Cancer.

[55]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[56]  Nicola Zamboni,et al.  High-throughput quantitative metabolomics: workflow for cultivation, quenching, and analysis of yeast in a multiwell format. , 2009, Analytical chemistry.

[57]  Jacob D. Feala,et al.  Search Algorithms as a Framework for the Optimization of Drug Combinations , 2008, PLoS Comput. Biol..

[58]  L. S. Harrington,et al.  Restraining PI3K: mTOR signalling goes back to the membrane. , 2005, Trends in biochemical sciences.

[59]  U. Sauer,et al.  Metabolic flux profiling of Escherichia coli mutants in central carbon metabolism using GC-MS. , 2003, European journal of biochemistry.

[60]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[61]  U. Günther,et al.  Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. , 2009, Neoplasia.

[62]  W. Kofke,et al.  Potential Non-Hypoxic/Ischemic Causes of Increased Cerebral Interstitial Fluid Lactate/Pyruvate Ratio: A Review of Available Literature , 2011, Neurocritical care.

[63]  G. de Pinieux,et al.  Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. , 2003, British journal of clinical pharmacology.

[64]  Ying Zhang,et al.  HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..